| Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites (NCT04267575) | Jerome Canady, M.D. | 2019-07-30 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCT03682289) | Rahul Aggarwal | 2019-01-17 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer (NCT03092856) | University of Southern California | 2017-07-19 |
| Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer (NCT02899078) | University of California, Davis | 2016-11-15 |
| Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor (NCT02944617) | City of Hope Medical Center | 2016-11-11 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors (NCT02650635) | Mayo Clinic | 2016-02-05 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319) | Mayo Clinic | 2016-01-01 |
| 18F-FSPG PET/CT for Cancer Patients on Therapy (NCT02599194) | Andrei Iagaru | 2015-07-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer (NCT02542202) | University of Chicago | 2015-05-01 |
| Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors (NCT02526511) | Rutgers, The State University of New Jersey | 2015-04-01 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery (NCT02166255) | Wake Forest University Health Sciences | 2014-12-01 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (NCT02273752) | Emory University | 2014-11-01 |
| Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer (NCT01943188) | Stanford University | 2014-05-01 |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers (NCT01846520) | City of Hope Medical Center | 2013-10-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery (NCT01892930) | Roswell Park Cancer Institute | 2013-07-11 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer (NCT01767636) | Mayo Clinic | 2013-05-16 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy (NCT01806675) | Sanjiv Sam Gambhir | 2013-03-04 |
| Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer (NCT01727076) | National Cancer Institute (NCI) | 2013-02-15 |
| Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer (NCT01826877) | Jonsson Comprehensive Cancer Center | 2013-01-14 |
| Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer (NCT01684397) | Roswell Park Cancer Institute | 2012-11-21 |
| Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (NCT01727089) | National Cancer Institute (NCI) | 2012-11-01 |
| Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer (NCT01740154) | Case Comprehensive Cancer Center | 2012-09-01 |
| Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery (NCT01688973) | National Cancer Institute (NCI) | 2012-08-20 |
| Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer (NCT01599832) | University of Chicago | 2012-06-01 |
| Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01548482) | National Cancer Institute (NCI) | 2012-03-01 |
| Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer (NCT01157091) | City of Hope Medical Center | 2010-12-08 |
| A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET) (NCT01265368) | Mologen AG | 2010-11-01 |
| Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies (NCT01243359) | National Cancer Institute (NCI) | 2010-10-01 |
| Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer (NCT01158222) | Case Comprehensive Cancer Center | 2010-08-18 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors (NCT01198184) | National Cancer Institute (NCI) | 2010-08-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy (NCT01141569) | National Cancer Institute (NCI) | 2010-06-01 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (NCT01131234) | National Cancer Institute (NCI) | 2010-05-01 |
| Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate (NCT01582009) | Roswell Park Cancer Institute | 2010-03-01 |
| Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery (NCT01061411) | Roswell Park Cancer Institute | 2010-02-06 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer (NCT01026337) | Abramson Cancer Center at Penn Medicine | 2009-04-01 |
| Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer (NCT00684996) | National Cancer Institute (NCI) | 2008-06-01 |
| Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors (NCT00499135) | National Cancer Institute (NCI) | 2007-05-22 |
| Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer (NCT00408902) | National Cancer Institute (NCI) | 2006-11-01 |
| AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery (NCT00348699) | National Cancer Institute (NCI) | 2006-07-01 |
| Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors (NCT00335556) | Children's Oncology Group | 2006-06-01 |
| Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00354250) | National Cancer Institute (NCI) | 2006-05-01 |
| AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer (NCT00303862) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer (NCT00324740) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer (NCT00324870) | National Cancer Institute (NCI) | 2006-02-01 |
| Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery (NCT00227760) | National Cancer Institute (NCI) | 2005-12-01 |
| Vorinostat in Treating Patients With Kidney Cancer (NCT00278395) | National Cancer Institute (NCI) | 2005-10-01 |
| Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer (NCT00182702) | National Cancer Institute (NCI) | 2005-07-01 |
| Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery (NCT00217542) | National Cancer Institute (NCI) | 2005-07-01 |
| Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer (NCT00126594) | National Cancer Institute (NCI) | 2005-06-01 |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer (NCT00126503) | National Cancer Institute (NCI) | 2005-05-01 |
| CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00112840) | National Cancer Institute (NCI) | 2005-05-01 |
| Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer (NCT00126490) | National Cancer Institute (NCI) | 2005-03-01 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (NCT00655655) | Mayo Clinic | 2004-12-01 |
| Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (NCT00098618) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00101114) | National Cancer Institute (NCI) | 2004-09-01 |
| Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer (NCT00083109) | National Cancer Institute (NCI) | 2004-03-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer (NCT00059813) | National Cancer Institute (NCI) | 2003-08-01 |
| Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer (NCT00060307) | National Cancer Institute (NCI) | 2003-05-01 |
| Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer (NCT00032188) | National Cancer Institute (NCI) | 2002-01-01 |
| Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer (NCT00005851) | Fred Hutchinson Cancer Center | 2000-02-01 |
| Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00005799) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer (NCT00019539) | National Cancer Institute (NCI) | 1998-11-01 |
| flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer (NCT00019396) | National Cancer Institute (NCI) | 1998-02-01 |
| BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer (NCT00040989) | Jonsson Comprehensive Cancer Center | |